carfilzomib
Showing 1 - 25 of 133
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
- Elranatamab
- Carfilzomib
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Chicago, IllinoisUniversity of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023
Carfilzomib in Patients With Multiple Myeloma
Recruiting
- Multiple Myeloma
- Carfilzomib
-
Odense, DenmarkOdense University Hospital
Dec 20, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 14, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyFondazione EMN Italy Onlus
Mar 24, 2022
Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)
Not yet recruiting
- Multiple Myeloma
- Dexamethasone
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyFondazione EMN Italy Onlus
Mar 24, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022
Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)
Completed
- Hematologic Malignancies
- +2 more
- Carfilzomib
- Tacrolimus
-
Ann Arbor, MichiganUniversity of Michigan Hospital
Dec 3, 2021
Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Oct 5, 2021
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)
Recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Nov 25, 2021
Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)
Recruiting
- Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Chicago, IllinoisThe University of Chicago
Sep 15, 2021
Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)
Recruiting
- Multiple Myeloma
- Selinexor 60 MG
- +6 more
-
Washington, District of Columbia
- +1 more
Feb 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Aug 8, 2022
Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Basking Ridge, New Jersey
- +5 more
Nov 18, 2021
Hodgkin Disease, Lymphoma, Non-hodgkin Trial in New York (Carfilzomib, TGR-1202)
Terminated
- Hodgkin Disease
- Lymphoma, Non-hodgkin
- Carfilzomib
- TGR-1202
-
New York, New YorkColumbia University Irving Medical Center - Center for Lymphoid
Jun 28, 2021
Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)
Recruiting
- Smouldering Myeloma
- Carfilzomib
- +2 more
-
Brno, Czechia
- +15 more
Mar 22, 2022
MULTIPLE MYELOMA (MM) Trial in Rionero in Vulture (Carfilzomib, Cyclophosphamide, Lenalidomide)
Active, not recruiting
- MULTIPLE MYELOMA (MM)
- Carfilzomib
- +3 more
-
Rionero in Vulture, ItalyIRCCS--CROB --CROB di Rionero in di Rionero in Vulture
Apr 28, 2021